A Pro-Regenerative Supramolecular Prodrug Protects Against and Repairs Colon Damage in Experimental Colitis

Area of Science:

• Gastroenterology
• Regenerative Medicine
• Pharmacology

Background:

• Intestinal ulcer healing is crucial for inflammatory bowel disease (IBD) remission but is not targeted by current therapies.
• Hypoxia-inducible factor one-alpha (HIF-1α) plays a role in tissue repair and regeneration.

Purpose of the Study:

• To investigate the potential of a prolyl hydroxylase (PHD) inhibitor, DPCA, to induce mammalian intestinal regeneration.
• To assess the efficacy of DPCA delivered via a self-assembling hydrogel for treating IBD-induced colitis.

Main Methods:

• Development of a supramolecular hydrogel for sustained subcutaneous delivery of PEG-DPCA conjugates.
• Administration of PEG-DPCA to mice with dextran sodium sulfate (DSS)-induced colitis, both as pre-treatment and post-disease onset.
• Evaluation of therapeutic effects through monitoring weight gain, tissue architecture, and epithelial barrier integrity.

Main Results:

• Pre-treatment with PEG-DPCA protected against DSS-induced colitis symptoms and epithelial erosion.
• A single dose of PEG-DPCA administered after disease onset accelerated weight gain and fully restored colonic tissue architecture.
• DPCA treatment upregulated HIF-1α expression, suggesting a mechanism involving epithelial-to-mesenchymal transition for barrier restoration.

Conclusions:

• DPCA, delivered via a hydrogel, demonstrates significant potential for promoting intestinal regeneration and healing in IBD.
• DPCA shows promise as an adjunctive or stand-alone therapy for active IBD, addressing the unmet need for ulcer healing.
• Further research into DPCA's restorative capabilities in IBD is warranted.